PACUPod is your trusted source for evidence-based insights tailored to advanced clinical pharmacists and physicians. Each episode dives into the latest primary literature, covering medication-focused studies across specialty pharmacy, and many more. We break down study designs, highlight key findings, and objectively discuss clinical implications—without the hype—so you stay informed and ready to apply new evidence in practice. Whether you’re preparing for board certification or striving for excellence in patient care, PACUPod helps you make sense of the data, one study at a time.
Britany: Welcome back to PACULit, your go-to source for clinical literature updates. Today, we’re discussing the IMMbrace phase three trial from Brazil, which compared risankizumab to methotrexate in moderate-to-severe plaque psoriasis. Seth, this is a particularly relevant topic given the evolving landscape of systemic treatments for psoriasis.
Seth: Absolutely, Britany. Moderate-to-severe plaque psoriasis affects approximately two to three percent of the global population and significantly impacts patients’ quality of life. Methotrexate has long been a mainstay systemic therapy, but it carries safety concerns such as hepatotoxicity and cytopenias that require careful monitoring.
Britany: That’s exactly where biologic therapies like risankizumab come into play. Risankizumab targets interleukin twenty-three, a key cytokine in psoriasis pathogenesis. While previous studies have demonstrated its promising efficacy, the IMMbrace trial provides direct head-to-head data comparing risankizumab to methotrexate, particularly in a Latin American population.
Seth: To give some details, IMMbrace randomized ninety-eight adults with moderate-to-severe plaque psoriasis across multiple centers in Brazil. Participants were assigned to receive either risankizumab or methotrexate. The primary endpoint was achieving a ninety percent improvement in the Psoriasis Area and Severity Index, or PASI ninety, at twenty-eight weeks.
Britany: Regarding dosing, risankizumab was administered as one hundred fifty milligrams subcutaneously at baseline, again at week four, and then every twelve weeks thereafter. Methotrexate dosing ranged from five to twenty-five milligrams weekly, given either orally or subcutaneously, based on investigator discretion.
Seth: The study employed a double-blind design, using placebo injections and matching tablets to maintain blinding for both patients and investigators. This approach strengthens the internal validity of the trial.
Britany: Secondary outcomes included the static Physician’s Global Assessment, or sPGA, with scores of zero or one indicating clear or almost clear skin, as well as PASI one hundred, which represents complete skin clearance. Safety was monitored through an open-label extension lasting up to one hundred twelve weeks.
Seth: The trial enrolled forty-nine patients per treatment arm, with a mean age of forty-five years. Gender distribution was balanced, and most participants had Fitzpatrick skin types three and four, reflecting the Brazilian demographic.
Britany: Baseline disease severity was moderate-to-severe, defined as a PASI score of at least twelve, body surface area involvement of ten percent or greater, and an sPGA score of three or higher.
Seth: The results were striking. At week twenty-eight, eighty-four percent of patients receiving risankizumab achieved PASI ninety compared to thirty-five point four percent in the methotrexate group. This difference was statistically significant with a p-value less than zero point zero zero one.
Britany: Similarly, for the sPGA endpoint of zero or one, ninety percent of patients on risankizumab reached this target versus sixty-four point six percent on methotrexate, also a significant difference. Rates of PASI one hundred were higher with risankizumab as well.
Seth: Safety profiles were comparable between the two groups, with no unexpected adverse events reported. Serious adverse event rates were low and similar, supporting risankizumab’s favorable safety profile.
Britany: The open-label extension demonstrated sustained efficacy of risankizumab through one hundred twelve weeks, reinforcing its role not only in induction but also in long-term maintenance therapy.
Seth: These findings align with prior phase three studies such as UltIMMa and IMMvent, which showed risankizumab’s superiority over ustekinumab and adalimumab. IMMbrace adds valuable direct comparison data against methotrexate in a real-world setting.
Britany: Meta-analyses, including a Cochrane review published in twenty twenty-five, consistently rank interleukin twenty-three inhibitors like risankizumab highest in terms of efficacy and safety among systemic psoriasis treatments.
Seth: Clinically, risankizumab’s infrequent dosing schedule—every twelve weeks after the initial doses—may improve patient adherence compared to weekly methotrexate, which requires frequent laboratory monitoring for hepatotoxicity and cytopenias.
Britany: Methotrexate’s safety concerns necessitate regular blood tests, which can be burdensome for patients. In contrast, risankizumab’s safety profile and less frequent dosing may enhance quality of life and reduce the need for intensive monitoring.
Seth: It is important to note that IMMbrace excluded patients with significant hepatic impairment or active infections, which is standard for biologic trials. Clinicians should remain vigilant for infections, particularly tuberculosis reactivation, although interleukin twenty-three inhibitors generally carry a lower risk than tumor necrosis factor alpha blockers.
Britany: Drug interactions are another consideration. Methotrexate interacts with medications such as trimethoprim-sulfamethoxazole and nonsteroidal anti-inflammatory drugs, increasing toxicity risk. Risankizumab, being a monoclonal antibody, has fewer drug interactions, simplifying management, especially in patients on multiple medications.
Seth: Regarding special populations, IMMbrace primarily included adults without significant comorbidities. More data are needed on risankizumab’s safety in patients with hepatic or renal impairment, during pregnancy, or with latent infections.
Britany: The Brazilian cohort adds important diversity, addressing a gap since many psoriasis trials focus predominantly on North American and European populations. This enhances the generalizability of the findings to Latin American patients.
Seth: Limitations of the study include the relatively small sample size of ninety-eight patients, which limits detailed subgroup analyses, and the single-country design, which may affect extrapolation to other ethnic groups or healthcare systems.
Britany: Nevertheless, the randomized, double-blind design and clinically relevant endpoints such as PASI ninety and sPGA strengthen the conclusions. The open-label extension provides valuable long-term data, though open-label phases can introduce some bias.
Seth: Future real-world effectiveness and cost-effectiveness studies will be important to optimize risankizumab’s global positioning. Access and affordability remain challenges, particularly in resource-limited settings.
Britany: Clinically, IMMbrace supports considering risankizumab as a preferred systemic agent for moderate-to-severe plaque psoriasis, especially for patients with contraindications or intolerance to methotrexate.
Seth: Sustained efficacy with infrequent dosing and a favorable safety profile make risankizumab an attractive option for long-term management—a meaningful step forward in personalized psoriasis care.
Britany: To summarize, IMMbrace provides robust evidence that risankizumab is superior to methotrexate in achieving high levels of skin clearance at twenty-eight weeks, with comparable safety and sustained benefits over two years.
Seth: This trial fills a knowledge gap by directly comparing these agents in a Latin American population, reinforcing risankizumab’s role as a leading systemic therapy for moderate-to-severe plaque psoriasis.
Britany: Before we wrap up, Seth, it’s worth highlighting the patient-reported outcomes in IMMbrace. Although not the primary focus, improvements in quality of life measures, such as the Dermatology Life Quality Index, paralleled the clinical efficacy results. Patients on risankizumab reported greater reductions in itch, pain, and social stigma compared to those on methotrexate.
Seth: That is an excellent point, Britany. Psoriasis is more than skin deep; the psychosocial burden is substantial. Treatments that not only clear skin but also improve patient well-being holistically are essential. The rapid onset of action with risankizumab likely contributes to these quality of life gains.
Britany: Another clinical consideration is immunogenicity. Risankizumab, as a fully humanized monoclonal antibody, has a low incidence of anti-drug antibodies, which can affect efficacy and safety. Methotrexate, being a small molecule, does not have this issue but carries other risks.
Seth: Regarding safety, the trial showed no new safety signals with risankizumab, but clinicians should remain vigilant for rare adverse events such as hypersensitivity reactions or new-onset inflammatory bowel disease, which have been reported in post-marketing surveillance.
Britany: Methotrexate’s hepatotoxicity risk is well known and is both dose-dependent and cumulative. The trial’s flexible dosing allowed titration, but in clinical practice, liver function monitoring every four to twelve weeks is standard, which can be cumbersome for patients.
Seth: In contrast, risankizumab’s safety monitoring is less intensive, typically involving baseline screening for latent tuberculosis and routine clinical assessments. This difference can reduce healthcare utilization and patient burden.
Britany: From a pharmacoeconomic perspective, although biologics like risankizumab have higher upfront costs, their superior efficacy, safety, and dosing convenience may translate into cost savings by reducing disease flares, hospitalizations, and productivity loss.
Seth: That is an important consideration for payers and healthcare systems. Additionally, patient preference often favors less frequent injections over weekly oral medications, potentially improving adherence and long-term outcomes.
Britany: Looking ahead, combination strategies are being explored. For example, low-dose methotrexate combined with biologics may mitigate immunogenicity and enhance efficacy, though more data are needed specifically with risankizumab.
Seth: Absolutely. Personalized medicine approaches, incorporating genetic, immunologic, and lifestyle factors, will further refine treatment selection. Trials like IMMbrace provide foundational data to guide these advances.
Britany: Lastly, it is encouraging to see more trials conducted in diverse populations. Ethnic and genetic variability can influence drug response and safety, so including underrepresented groups improves the applicability of findings worldwide.
Seth: Well said, Britany. As clinicians, staying informed about emerging evidence helps us tailor therapies to individual patient needs, balancing efficacy, safety, and quality of life.
Britany: Could not agree more. Thanks again for this insightful discussion, Seth.
Seth: Thank you, Britany. And thanks to our listeners for tuning in. Remember, continuous learning is key to delivering the best patient care. See you next time on PACULit!